This product is a central anticholinergic anti-Parkinson's disease drug that selectively blocks the cholinergic nerve pathways in the striatum, but has less effect on the periphery, thus helping to restore the balance of dopamine and acetylcholine in the brain of Parkinson's patients and improve the patients' Parkinson's disease symptoms.

This product is a dopamine 2 (D2) receptor antagonist, and also has a 5-hydroxytryptamine 4 (5-HT4) receptor agonist effect, and has a mild inhibitory effect on 5-HT3 receptors. It can act on dopamine receptors in the medullary chemo-emetic zone (CTZ) to increase the threshold of CTZ, and has a strong central antiemetic effect. This product can also block hypothalamic dopamine receptors, inhibit prolactin inhibitory factor, and promote the secretion of prolactin, so it has a certain lactation effect. The inhibitory effect on other parts of the central nervous system is relatively small, with a weak sedative effect and less hypnotic effect. The main effect on the gastrointestinal tract is on the upper digestive tract, promoting the movement of the stomach and upper intestinal segments; increasing the tension of the gastrointestinal sphincter in the resting state, increasing the tension and contraction amplitude of the lower esophageal sphincter, increasing the pressure at the lower end of the esophagus, blocking gastroesophageal reflux, strengthening gastric and esophageal peristalsis, and enhancing the ability to clear the contents of the esophagus, promoting gastric emptying; promoting the relaxation of the pylorus, duodenum and upper jejunum, forming functional coordination between the gastric antrum, gastric body and upper small intestine. These effects can also enhance the antiemetic effect of this product. The transmission effect of this product on the small intestine and colon is still uncertain.

Can neutralize stomach acid and protect ulcer surface

Can promote granulation development and mucosal regeneration

It can inhibit glandular secretion and relieve pain caused by smooth spasm

It has a broad-spectrum antimicrobial effect in vitro, including aerobic Gram-negative and Gram-positive bacteria, anaerobes, Rickettsia, spirochetes and Chlamydia. It has a bactericidal effect on Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis; it only has an antibacterial effect on anaerobic bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Group B hemolytic Streptococcus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhi, Salmonella paratyphi, Shigella, Bacteroides fragilis, etc. Pseudomonas aeruginosa, Acinetobacter, Enterobacter, Serratia marcescens, indole-positive Proteus, methicillin-resistant Staphylococcus and Enterococcus are usually resistant to it. Chloramphenicol is fat-soluble, enters bacterial cells by diffusion, and reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting the action of transpeptidase, thereby preventing protein synthesis.

1. Stimulate the pancreatic islet beta cells to secrete insulin, which presupposes that the islet beta cells also have a certain ability to synthesize and secrete insulin. 2. By increasing portal vein insulin levels or acting directly on the liver, inhibiting liver glycogenolysis and gluconeogenesis, the liver produces and outputs less glucose. 3. It may also increase the sensitivity of extrapancreatic tissues to insulin and the utilization of sugar (probably mainly through post-receptor effects). Therefore, the overall effect is to reduce fasting blood sugar and postprandial blood sugar.